-
1
-
-
84865462085
-
Stiripentol: an example of antiepileptic drug development in childhood epilepsies
-
Nabbout R., Chiron C. Stiripentol: an example of antiepileptic drug development in childhood epilepsies. Eur J Paediatr Neurol 2012, 16:S13-S17.
-
(2012)
Eur J Paediatr Neurol
, vol.16
, pp. S13-S17
-
-
Nabbout, R.1
Chiron, C.2
-
2
-
-
0032724018
-
Stiripentol: efficacy and tolerability in children with epilepsy
-
Perez J., Chiron C., Musial C., Rey E., Blehaut H., d'Athis P., et al. Stiripentol: efficacy and tolerability in children with epilepsy. Epilepsia 1999, 40:1618-1626.
-
(1999)
Epilepsia
, vol.40
, pp. 1618-1626
-
-
Perez, J.1
Chiron, C.2
Musial, C.3
Rey, E.4
Blehaut, H.5
d'Athis, P.6
-
3
-
-
0034638786
-
Stiripentol in severe myoclonic epilepsy in infancy: a randomised placebo-controlled syndrome-dedicated trial
-
Chiron C., Marchand M.C., Tran A., Rey E., d'Athis P., Vincent J., et al. Stiripentol in severe myoclonic epilepsy in infancy: a randomised placebo-controlled syndrome-dedicated trial. Lancet 2000, 356:1638-1642.
-
(2000)
Lancet
, vol.356
, pp. 1638-1642
-
-
Chiron, C.1
Marchand, M.C.2
Tran, A.3
Rey, E.4
d'Athis, P.5
Vincent, J.6
-
4
-
-
33645106149
-
In vitro and in vivo inhibitory effect of stiripentol on clobazam metabolism
-
Giraud C., Treluyer J.M., Rey E., Chiron C., Vincent J., Pons G., et al. In vitro and in vivo inhibitory effect of stiripentol on clobazam metabolism. Drug Metab Dispos 2006, 34:608-611.
-
(2006)
Drug Metab Dispos
, vol.34
, pp. 608-611
-
-
Giraud, C.1
Treluyer, J.M.2
Rey, E.3
Chiron, C.4
Vincent, J.5
Pons, G.6
-
5
-
-
70350401140
-
Stiripentol open study in Japanese patients with Dravet syndrome
-
Inoue Y., Ohtsuka Y., Oguni H., Tohyama J., Baba H., Fukushima K., et al. Stiripentol open study in Japanese patients with Dravet syndrome. Epilepsia 2009, 50:2362-2368.
-
(2009)
Epilepsia
, vol.50
, pp. 2362-2368
-
-
Inoue, Y.1
Ohtsuka, Y.2
Oguni, H.3
Tohyama, J.4
Baba, H.5
Fukushima, K.6
-
6
-
-
15444340367
-
A new genetic defect in human CYP2C19: mutation of the initiation codon is responsible for poor metabolism of S-mephenytoin
-
Ferguson R.J., De Morais S.M., Benhamou S., Bouchardy C., Blaisdell J., Ibeanu G., et al. A new genetic defect in human CYP2C19: mutation of the initiation codon is responsible for poor metabolism of S-mephenytoin. J Pharmacol Exp Ther 1998, 284:356-361.
-
(1998)
J Pharmacol Exp Ther
, vol.284
, pp. 356-361
-
-
Ferguson, R.J.1
De Morais, S.M.2
Benhamou, S.3
Bouchardy, C.4
Blaisdell, J.5
Ibeanu, G.6
-
7
-
-
7744226277
-
A major influence of CYP2C19 genotype on the steady-state concentration of N-desmethylclobazam
-
Kosaki K., Tamura K., Sato R., Samejima H., Tanigawara Y., Takahashi T. A major influence of CYP2C19 genotype on the steady-state concentration of N-desmethylclobazam. Brain Dev 2004, 26:530-534.
-
(2004)
Brain Dev
, vol.26
, pp. 530-534
-
-
Kosaki, K.1
Tamura, K.2
Sato, R.3
Samejima, H.4
Tanigawara, Y.5
Takahashi, T.6
-
8
-
-
43349103389
-
A screening test for the prediction of Dravet syndrome before one year of age
-
Hattori J., Ouchida M., Ono J., Miyake S., Maniwa S., Mimaki N., et al. A screening test for the prediction of Dravet syndrome before one year of age. Epilepsia 2008, 49:626-633.
-
(2008)
Epilepsia
, vol.49
, pp. 626-633
-
-
Hattori, J.1
Ouchida, M.2
Ono, J.3
Miyake, S.4
Maniwa, S.5
Mimaki, N.6
-
9
-
-
0344672944
-
Mutations of sodium channel alpha subunit type 1 (SCN1A) in intractable childhood epilepsies with frequent generalized tonic-clonic seizures
-
Fujiwara T., Sugawara T., Mazaki-Miyazaki E., Takahashi Y., Fukushima K., Watanabe M., et al. Mutations of sodium channel alpha subunit type 1 (SCN1A) in intractable childhood epilepsies with frequent generalized tonic-clonic seizures. Brain 2003, 126:531-546.
-
(2003)
Brain
, vol.126
, pp. 531-546
-
-
Fujiwara, T.1
Sugawara, T.2
Mazaki-Miyazaki, E.3
Takahashi, Y.4
Fukushima, K.5
Watanabe, M.6
-
11
-
-
6944252142
-
In vitro characterization of clobazam metabolism by recombinant cytochrome p450 enzymes: importance of CYP2C19
-
Giraud C., Tran A., Rey E., Vincent J., Tréluyer J.M., Pons G. In vitro characterization of clobazam metabolism by recombinant cytochrome p450 enzymes: importance of CYP2C19. Drug Metab Dispos 2004, 32:1279-1286.
-
(2004)
Drug Metab Dispos
, vol.32
, pp. 1279-1286
-
-
Giraud, C.1
Tran, A.2
Rey, E.3
Vincent, J.4
Tréluyer, J.M.5
Pons, G.6
-
12
-
-
35648994906
-
Efficacy of low-dose, add-on therapy of clobazam(CLB) is produced by its major metabolite, N-desmethyl-CLB
-
Kinoshita M., Ikeda A., Begum T., Terada K., Shibasaki H. Efficacy of low-dose, add-on therapy of clobazam(CLB) is produced by its major metabolite, N-desmethyl-CLB. J Neurol Sci 2007, 263:44-48.
-
(2007)
J Neurol Sci
, vol.263
, pp. 44-48
-
-
Kinoshita, M.1
Ikeda, A.2
Begum, T.3
Terada, K.4
Shibasaki, H.5
-
13
-
-
58049084097
-
A receptor as a positive allosteric modulator
-
A receptor as a positive allosteric modulator. Neuropharmacology 2009, 56:190-197.
-
(2009)
Neuropharmacology
, vol.56
, pp. 190-197
-
-
Fisher, J.L.1
-
14
-
-
79953728248
-
A receptors
-
A receptors. Epilepsia 2011, 52:76-78.
-
(2011)
Epilepsia
, vol.52
, pp. 76-78
-
-
Fisher, J.L.1
-
17
-
-
79955022433
-
Current therapeutic procedures in Dravet syndrome
-
Chiron C. Current therapeutic procedures in Dravet syndrome. Dev Med Child Neurol 2011, 53:16-18.
-
(2011)
Dev Med Child Neurol
, vol.53
, pp. 16-18
-
-
Chiron, C.1
-
18
-
-
79959974462
-
Ketogenic diet also benefits Dravet syndrome patients receiving stiripentol: a prospective pilot study
-
Nabbout R., Copioli C., Chipaux M., Chemaly N., Desguerre I., Dulac O., et al. Ketogenic diet also benefits Dravet syndrome patients receiving stiripentol: a prospective pilot study. Epilepsia 2011, 52:e54-e57.
-
(2011)
Epilepsia
, vol.52
, pp. e54-e57
-
-
Nabbout, R.1
Copioli, C.2
Chipaux, M.3
Chemaly, N.4
Desguerre, I.5
Dulac, O.6
|